A new generation of blood biomarkers is changing how we think about dementia prevention. A recent Lancet article highlighted how Alzheimer-related bloo d markers may detect risk years before symptoms appear [1]. A 2026 Nature Medicine study showed that plasma p-tau217 clocks could estimate the likely timing of symptomatic Alzheimer’s disease several years before onset [2]. This matters because dementia prevention is no longer just about reacting once memory problems begin.

For decades, dementia was framed as the unfortunate but unavoidable consequence of ageing or, for some, genetics. That story is no longer scientifically defensible. Two of the most credible recent population estimates tell a different story: “We estimated that the PAF for all 14 risk factors was 45.3%.” [1] And in England: “Overall, we estimate that up to 34.5% of dementia cases may be preventable.” [2] These figures don’t mean any individual can guarantee they won’t develop

By Dr Angus Perry. GP & Founder of GeneralPractice.AI This blog is for healthcare professionals looking for practical, evidence-based strategies to help patients who are struggling to lose weight, particularly those who may not qualify for, or have access to, GLP-1 based medications. It focuses on actionable lifestyle measures that can enhance satiety, improve metabolic health, and support sustainable weight loss. GLP-1 receptor agonists have been transformative. They are d